Earnings Call · Q2 FY2024·2024-07-25

Q2 24EPS +22.50%·Rev n/aQ1 24EPS +14.29%·Rev n/aQ4 23EPS +13.46%·Rev n/aQ3 23EPS +11.54%·Rev n/a⚠ consensus missing

NovoCure Ltd NVCR

Ingrid Goldberg — Investor Relations

Bill Doyle — Executive Chairman

Asaf Danziger — Chief Executive Officer

Ashley Cordova — Chief Financial Officer

−0.7%1d on move date−0.2% vs SPY3d+10.7%5d+21.2%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NVCR calls or request research access.

More NVCR calls Browse calls Request research access